Clinical Trials Browser

Enrolling by invitation × Stomach Neoplasms × 30 days × Clear all

Stomach Neoplasms

NCT07218003 2026-03-23

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07488312 2026-03-23

LUCENT-GC-01

Phase 1 Enrolling by invitation

37 enrolled

Gastrointestinal

Stomach Neoplasms

Clinical Trials

CGCA202501

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

LUCENT-GC-01